In terms of revenue, the global market was valued at US$ 28,280.0 Mn in 2018 and is projected to reach US$ 61,296.1 Mn by 2026, expanding at a CAGR of 9.5% from 2019 to 2026. The global prescription dermatology therapeutics market is also driven by rise in adoption of biologics for the treatment of moderate to severe dermatological disorders, especially psoriasis, and large patient population with unmet medical needs across the globe. The global prescription dermatology therapeutics market is growing at a rapid pace due to high prevalence and increase in incidence rate of chronic and infectious dermatological disorders, and new product development and commercialization across the globe.
The report analyzes and forecasts the prescription dermatology therapeutics market at global and regional levels. The market has been forecast based on volume (Tons) and value (US$ Mn) from 2019 to 2026. The study includes drivers and restraints of the global market. It covers the impact of these drivers and restraints on the demand during the forecast period. The report also highlights opportunities in the market at the global level. For the region and all segments, the sales, revenue and their market share, growth rate are key research objects; we can research the manufacturers' sales, price, revenue, cost and gross profit and their changes. What's more, we will display the main consumers, raw material manufacturers, distributors, etc.
This report first introduces the background of prescription dermatology therapeutics, including the definition, classification, application, industrial chain structure, industry overview, national policy and planning analysis of the industry, and the latest dynamic analysis. With regard to production bases and technologies, the research in this report covers the production time, base distribution, technical parameters, research and development trends, technology sources, and sources of raw materials of major prescription dermatology therapeutics companies.
Regarding the analysis of the industry chain, the research of this report covers the raw materials and equipment of prescription dermatology therapeutics upstream, downstream customers, marketing channels, industry development trends and investment strategy recommendations. The more specific analysis also includes the main application areas of prescription dermatology therapeutics and consumption, major regions and consumption, major global producers, distributors, raw material suppliers, equipment providers and their contact information, industry chain relationship analysis.
The report comprises a detailed value chain analysis, which provides a comprehensive view of the global prescription dermatology therapeutics market. The Porter’s Five Forces model has also been included to help understand the competitive landscape of the market. The study encompasses market attractiveness analysis, wherein various applications have been benchmarked based on their market size, growth rate, and general attractiveness.
The study provides a decisive view of the prescription dermatology therapeutics market by segmenting it in terms of form and application. The segment has been analyzed based on the present and future trends. Regional segmentation includes the current and projected demand in North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
The report provides size (in terms of volume and value) of prescription dermatology therapeutics market for the base year 2018 and the forecast between 2019 and 2026. Market numbers have been estimated based on form and application. Market size and forecast for each application segment have been provided for the global and regional market.
Competitive landscape
Major players operating in the global prescription dermatology therapeutics market include AbbVie, Inc., Janssen Biotech, Inc., Novartis AG, Amgen, Inc., Celgene Corporation, Pfizer, Inc., LEO Pharma A/S, Eli Lilly and Company, Bausch Health Companies, Inc., Sun Pharmaceuticals Ltd., Aclaris Therapeutics, Inc., and Aurobindo Pharma Ltd.
Report Segmentation:
Research Methodology:
In-depth interviews and discussions were conducted with several key market participants and opinion leaders to compile the research report.
Primary research represents a bulk of research efforts, supplemented by extensive secondary research. Annual reports, press releases, and relevant documents of key players operating in various application areas have been reviewed for competition analysis and market understanding.
Secondary research also includes recent trends, technical writing, Internet sources, and statistical data from government websites, trade associations, and agencies. These have proved to be reliable, effective, and successful approaches for obtaining precise market data, capturing market participants’ insights, and recognizing business opportunities.
The study objectives of this report are:
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary : Global Prescription Dermatology Therapeutics Market
4. Market Overview
4.1. Introduction
4.1.1. Product Type Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Prescription Dermatology Therapeutics Market Analysis and Forecast, 2018–2026
4.4.1. Market Revenue Projections (US$ Mn)
5. Market Outlook
5.1.Pipeline Analysis
5.2.Key Mergers & Acquisitions
5.3.Disease Prevalence & Incidence Rate globally with key countries
6. Global Prescription Dermatology Therapeutics Market Analysis and Forecast, by Product Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Product Type, 2018–2026
6.3.1. Acne & Rosacea Drugs
6.3.2. Psoriasis Drugs
6.3.3. Dermatitis & Seborrhea Drugs
6.3.4. Fungal Infection Drugs
6.3.5. Skin Cancer Drugs
6.3.6. Others
6.4. Market Attractiveness, by Product Type
7. Global Prescription Dermatology Therapeutics Market Analysis and Forecast, by Distribution Channel
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Distribution Channel, 2018–2026
7.3.1. Hospital Pharmacies
7.3.2. Retail Pharmacies
7.3.3. Mail Order Pharmacies
7.4. Market Attractiveness, by Distribution Channel
8. Global Prescription Dermatology Therapeutics Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Market Value Forecast, by Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness, by Country/Region
9. North America Prescription Dermatology Therapeutics Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Market Value Forecast, by Product Type, 2018–2026
9.2.1. Acne & Rosacea Drugs
9.2.2. Psoriasis Drugs
9.2.3. Dermatitis & Seborrhea Drugs
9.2.4. Fungal Infection Drugs
9.2.5. Skin Cancer Drugs
9.2.6. Others
9.3. Market Value Forecast, by Distribution Channel, 2018–2026
9.3.1. Hospital Pharmacies
9.3.2. Retail Pharmacies
9.3.3. Mail Order Pharmacies
9.4. Market Value Forecast, by Country, 2018–2026
9.4.1. U.S.
9.4.2. Canada
9.5. Market Attractiveness Analysis
9.5.1. By Product Type
9.5.2. By Distribution Channel
9.5.3. By Country
10. Europe Prescription Dermatology Therapeutics Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Product Type, 2018–2026
10.2.1. Acne & Rosacea Drugs
10.2.2. Psoriasis Drugs
10.2.3. Dermatitis & Seborrhea Drugs
10.2.4. Fungal Infection Drugs
10.2.5. Skin Cancer Drugs
10.2.6. Others
10.3. Market Value Forecast, by Distribution Channel, 2018–2026
10.3.1. Hospital Pharmacies
10.3.2. Retail Pharmacies
10.3.3. Mail Order Pharmacies
10.4. Market Value Forecast, by Country/Sub-region, 2018–2026
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Rest of Europe
10.5. Market Attractiveness Analysis
10.5.1. By Product Type
10.5.2. By Distribution Channel
10.5.3. By Country/Sub-region
11. Asia Pacific Prescription Dermatology Therapeutics Market Analysis and Forecast
11.1.Introduction
11.1.1. Key Findings
11.2.Market Value Forecast, by Product Type, 2018–2026
11.2.1. Acne & Rosacea Drugs
11.2.2. Psoriasis Drugs
11.2.3. Dermatitis & Seborrhea Drugs
11.2.4. Fungal Infection Drugs
11.2.5. Skin Cancer Drugs
11.2.6. Others
11.3.Market Value Forecast, by Distribution Channel, 2018–2026
11.3.1. Hospital Pharmacies
11.3.2. Retail Pharmacies
11.3.3. Mail Order Pharmacies
11.4.Market Value Forecast, by Country/Sub-region, 2018–2026
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia Pacific
11.5.Market Attractiveness Analysis
11.5.1. By Product Type
11.5.2. By Distribution Channel
11.5.3. By Country/Sub-region
12. Latin America Prescription Dermatology Therapeutics Market Analysis and Forecast
12.1.Introduction
12.1.1. Key Findings
12.2.Market Value Forecast, by Product Type, 2018–2026
12.2.1. Acne & Rosacea Drugs
12.2.2. Psoriasis Drugs
12.2.3. Dermatitis & Seborrhea Drugs
12.2.4. Fungal Infection Drugs
12.2.5. Skin Cancer Drugs
12.2.6. Others
12.3.Market Value Forecast, by Distribution Channel, 2018–2026
12.3.1. Hospital Pharmacies
12.3.2. Retail Pharmacies
12.3.3. Mail Order Pharmacies
12.4.Market Value Forecast, by Country/Sub-region, 2018–2026
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5.Market Attractiveness Analysis
12.5.1. By Product Type
12.5.2. By Distribution Channel
12.5.3. By Country/Sub-region
13. Middle East & Africa Prescription Dermatology Therapeutics Market Analysis and Forecast
13.1.Introduction
13.1.1. Key Findings
13.2.Market Value Forecast, by Product Type, 2018–2026
13.2.1. Acne & Rosacea Drugs
13.2.2. Psoriasis Drugs
13.2.3. Dermatitis & Seborrhea Drugs
13.2.4. Fungal Infection Drugs
13.2.5. Skin Cancer Drugs
13.2.6. Others
13.3 Market Value Forecast, by Distribution Channel, 2018–2026
13.3.1. Hospital Pharmacies
13.3.2. Retail Pharmacies
13.3.3. Mail Order Pharmacies
13.4.Market Value Forecast, by Country/Sub-region, 2018–2026
13.4.1. GCC Countries
13.4.2. South Africa
13.4.3. Rest of Middle East & Africa
13.5.Market Attractiveness Analysis
13.5.1. By Product Type
13.5.2. By Distribution Channel
13.5.3. By Country/Sub-region
14. Competition Landscape
14.1.Market Player - Competition Matrix (By Tier and Size of companies)
14.2.Market Share Analysis By Company (2017)
14.3. Company Profiles
14.3.1. AbbVie, Inc.
14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.1.2. Product Portfolio
14.3.1.3. SWOT Analysis
14.3.1.4. Financial Overview
14.3.1.5. Strategic Overview
14.3.2. Janssen Biotech, Inc.
14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.2.2. Product Portfolio
14.3.2.3. SWOT Analysis
14.3.2.4. Financial Overview
14.3.2.5. Strategic Overview
14.3.3. Novartis AG
14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.3.2. Product Portfolio
14.3.3.3. SWOT Analysis
14.3.3.4. Financial Overview
14.3.3.5. Strategic Overview
14.3.4. Amgen, Inc.
14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.4.2. Product Portfolio
14.3.4.3. SWOT Analysis
14.3.4.4. Financial Overview
14.3.4.5. Strategic Overview
14.3.5. Celgene Corporation
14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.5.2. Product Portfolio
14.3.5.3. SWOT Analysis
14.3.5.4. Financial Overview
14.3.5.5. Strategic Overview
14.3.6. Pfizer, Inc.
14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.6.2. Product Portfolio
14.3.6.3. SWOT Analysis
14.3.6.4. Financial Overview
14.3.6.5. Strategic Overview
14.3.7. LEO Pharma A/S
14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.7.2. Product Portfolio
14.3.7.3. SWOT Analysis
14.3.7.4. Financial Overview
14.3.7.5. Strategic Overview
14.3.8. Eli Lilly and Company
14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.8.2. Product Portfolio
14.3.8.3. SWOT Analysis
14.3.8.4. Financial Overview
14.3.8.5. Strategic Overview
14.3.9. Bausch Health Companies, Inc.
14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.9.2. Product Portfolio
14.3.9.3. SWOT Analysis
14.3.9.4. Financial Overview
14.3.9.5. Strategic Overview
14.3.10. Sun Pharmaceuticals Ltd.
14.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.10.2. Product Portfolio
14.3.10.3. SWOT Analysis
14.3.10.4. Financial Overview
14.3.10.5. Strategic Overview
14.3.11. Aclaris Therapeutics, Inc.
14.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.11.2. Product Portfolio
14.3.11.3. SWOT Analysis
14.3.11.4. Financial Overview
14.3.11.5. Strategic Overview
14.3.12. Aurobindo Pharma Ltd
14.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.12.2. Product Portfolio
14.3.12.3. SWOT Analysis
14.3.12.4. Financial Overview
14.3.12.5. Strategic Overview
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers